Plain-English translation of NCT06382103 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Researchers are studying blood samples from people with liver cancer who have undergone surgery. They want to look for specific markers in your blood — including tumor DNA and proteins — that might help doctors predict how well you'll do after surgery and decide on the best treatment plan for you.
Right now, doctors have limited tools to predict which patients will do well after liver cancer surgery and which ones might need additional treatment. By studying these blood markers, researchers hope to develop better ways to personalize care and catch cancer recurrence earlier.
You likely qualify if…
You likely don't qualify if…
You will have blood samples taken before and after your surgery so researchers can test them for tumor markers. The exact number of visits and how long you'll be followed isn't detailed in this summary, but your doctor can explain the specific schedule. This is an observational study, meaning you're not taking a new medication — the researchers are simply tracking information from your blood to learn more about your cancer.
AI-generated summary from trial data · Jun 13, 2026 · Not medical advice
China
Enrollment target
~240 participants
Started
May 2024
Primary completion
May 2025
This trial's estimated completion date has passed — the record may not be fully up to date.
Last updated on clinicaltrials.gov in March 2025.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Huichuan Sun
Shanghai Zhongshan Hospital
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.